Cryoablation technology company IceCure Medical (NASDAQ: ICCM) reported on Monday that commercial adoption and physician interest in its ProSense cryoablation system are increasing in Brazil following its recent US FDA clearance for the treatment of breast cancer.
The company highlighted growing momentum at the SOBRICE Onco 2026 interventional oncology congress, where clinicians presented clinical experience with ProSense. An independent Brazilian study, the SIX trial led by breast surgeon Vanessa Sanvido, is evaluating the technology in 750 breast cancer patients.
Separately, Toulsie Ramtohul of Institut Curie, who is set to lead the 900-patient CRYODESC breast cancer study in France, participated in the conference and delivered training sessions at hospitals in São Paulo.
IceCure said the growing clinical activity and physician engagement support wider commercial adoption of ProSense as a minimally invasive alternative to surgical tumour removal.
CVS Health expands GLP-1 weight management access through integrated care offering
Adyen to provide LillyDirect with payment technology services
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Acurx receives FDA guidance supporting ibezapolstat Phase 3 development strategy
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
Biocon launches Yesafili biosimilar in US ophthalmology market
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
European Commission approves RINVOQ for severe alopecia areata
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
RTW Biotech portfolio company Yarrow Bioscience completes merger
Lupin's Diazepam Injection, USP receives US approval
Auxilium Health changes name to Aeris Biosciences
Saol Therapeutics' SL1009 (DCA) resubmission accepted by FDA